110 related articles for article (PubMed ID: 9873388)
1. Synthesis of N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)nicotinamides and their affinities for 5-HT3 and dopamine D2 receptors.
Hirokawa Y; Yoshida N; Kato S
Bioorg Med Chem Lett; 1998 Jun; 8(12):1551-4. PubMed ID: 9873388
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
[TBL] [Abstract][Full Text] [Related]
3. A novel series of N-(hexahydro-1,4-diazepin-6-yl) and N-(hexahydroazepin- 3-yl)benzamides with high affinity for 5-HT3 and dopamine D2 receptors.
Hirokawa Y; Morie T; Yamazaki H; Yoshida N; Kato S
Bioorg Med Chem Lett; 1998 Mar; 8(6):619-24. PubMed ID: 9871571
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationships of 4-amino-5-chloro-N-(1,4-dialkylhexahydro-1,4-diazepin-6-yl)-2-methoxybenzamide derivatives, novel and potent serotonin 5-HT3 and dopamine D2 receptors dual antagonist.
Hirokawa Y; Harada H; Yoshikawa T; Yoshida N; Kato S
Chem Pharm Bull (Tokyo); 2002 Jul; 50(7):941-59. PubMed ID: 12130853
[TBL] [Abstract][Full Text] [Related]
5. Nitrogen-containing heteroalicycles with serotonin receptor binding affinity: development of gastroprokinetic and antiemetic agents.
Kato S; Fujiwara I; Yoshida N
Med Res Rev; 1999 Jan; 19(1):25-73. PubMed ID: 9918193
[TBL] [Abstract][Full Text] [Related]
6. An efficient synthesis of 5-bromo-2-methoxy-6-methylaminopyridine-3carboxylic acid.
Hirokawa Y; Horikawa T; Kato S
Chem Pharm Bull (Tokyo); 2000 Dec; 48(12):1847-53. PubMed ID: 11145130
[TBL] [Abstract][Full Text] [Related]
7. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
Yoshikawa T; Yoshida N; Oka M
Br J Pharmacol; 2001 May; 133(2):253-60. PubMed ID: 11350861
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
Orjales A; Alonso-Cires L; López-Tudanca PL; Tapia I; Labeaga L; Mosquera R
Drug Des Discov; 2000; 16(4):271-9. PubMed ID: 10807033
[TBL] [Abstract][Full Text] [Related]
9. Development of potent serotonin-3 (5-HT3) receptor antagonists. II. Structrue-activity relationships of N-(1-benzyl-4-methylhexahydro-1H-1,4- diazepin-6-yl)carboxamides.
Harada H; Morie T; Hirokawa Y; Terauchi H; Fujiwara I; Yoshida N; Kato S
Chem Pharm Bull (Tokyo); 1995 Nov; 43(11):1912-30. PubMed ID: 8575032
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of naphthamides as dopamine D3 receptor ligands.
Huang Y; Luedtke RR; Freeman RA; Wu L; Mach RH
J Med Chem; 2001 May; 44(11):1815-26. PubMed ID: 11356115
[TBL] [Abstract][Full Text] [Related]
11. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
Andersen K; Liljefors T; Hyttel J; Perregaard J
J Med Chem; 1996 Sep; 39(19):3723-38. PubMed ID: 8809161
[TBL] [Abstract][Full Text] [Related]
12. trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines: a new class of potent and selective 5-HT(1A) receptor ligands as conformationally constrained analogues of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines.
Perrone R; Berardi F; Colabufo NA; Leopoldo M; Lacivita E; Tortorella V; Leonardi A; Poggesi E; Testa R
J Med Chem; 2001 Dec; 44(25):4431-42. PubMed ID: 11728188
[TBL] [Abstract][Full Text] [Related]
13. N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: a potent and selective dopamine D4 ligand.
Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
J Med Chem; 1998 Nov; 41(24):4903-9. PubMed ID: 9822559
[TBL] [Abstract][Full Text] [Related]
14. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.
Wong EH; Clark R; Leung E; Loury D; Bonhaus DW; Jakeman L; Parnes H; Whiting RL; Eglen RM
Br J Pharmacol; 1995 Feb; 114(4):851-9. PubMed ID: 7773546
[TBL] [Abstract][Full Text] [Related]
15. New benzamide-derived 5-HT3 receptor antagonists which prevent the effects of ethanol on extracellular dopamine, and fail to reduce voluntary alcohol intake in rats.
Iusco G; Boido V; Sparatore F; Colombo G; Saba PL; Rossetti Z; Vaccari A
Farmaco; 1997 Mar; 52(3):141-6. PubMed ID: 9212448
[TBL] [Abstract][Full Text] [Related]
16. 1-aryl-4-[(5-methoxy-1,2,3, 4-tetrahydronaphthalen-1-yl)alkyl]piperazines and their analogues: influence of the stereochemistry of the tetrahydronaphthalen-1-yl nucleus on 5-HT1A receptor affinity and selectivity versus alpha1 and D2 receptors. 5.
Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
J Med Chem; 1999 Feb; 42(3):490-6. PubMed ID: 9986719
[TBL] [Abstract][Full Text] [Related]
17. Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics.
Raviña E; Negreira J; Cid J; Masaguer CF; Rosa E; Rivas ME; Fontenla JA; Loza MI; Tristán H; Cadavid MI; Sanz F; Lozoya E; Carotti A; Carrieri A
J Med Chem; 1999 Jul; 42(15):2774-97. PubMed ID: 10425088
[TBL] [Abstract][Full Text] [Related]
18. Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors.
Hamik A; Peroutka SJ
Cancer Chemother Pharmacol; 1989; 24(5):307-10. PubMed ID: 2527092
[TBL] [Abstract][Full Text] [Related]
19. Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands.
Leopoldo M; Berardi F; Colabufo NA; De Giorgio P; Lacivita E; Perrone R; Tortorella V
J Med Chem; 2002 Dec; 45(26):5727-35. PubMed ID: 12477356
[TBL] [Abstract][Full Text] [Related]
20. 11-substituted (R)-aporphines: synthesis, pharmacology, and modeling of D2A and 5-HT1A receptor interactions.
Hedberg MH; Linnanen T; Jansen JM; Nordvall G; Hjorth S; Unelius L; Johansson AM
J Med Chem; 1996 Aug; 39(18):3503-13. PubMed ID: 8784448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
